Angela M. Valverde and Pilar Valdecantos, researchers from IIB-CSIC, have attended the annual meeting of the European Association for the Study of Diabetes in Vienna (15-19th September, 2025) in which presented two short oral communications entitled: “A novel tetra-agonist peptide targeting GLP-1, GIP, amylin and calcitonin receptors with superior weight loss effects vs tirzepatide while preserving muscle in DIO rats” and “Beneficial effects of the combinatory therapy with sub-maximal doses of cagrilintide and tirzepatide on body weight loss in obese rats”
